European Neuropsychopharmacology最新文献

{"title":"On the potential of xanomeline-trospium chloride for schizophrenia and beyond","authors":"Nicholas Fabiano , Stanley Wong , Carl Zhou , Christoph U. Correll , Mikkel Højlund , Marco Solmi","doi":"10.1016/j.euroneuro.2025.02.002","DOIUrl":"10.1016/j.euroneuro.2025.02.002","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 17-18"},"PeriodicalIF":6.1,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence in healthcare: Revolution or unfulfilled promise?","authors":"Gerard Anmella , Enrique Baca-García","doi":"10.1016/j.euroneuro.2025.01.006","DOIUrl":"10.1016/j.euroneuro.2025.01.006","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 1-3"},"PeriodicalIF":6.1,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescription sequences in bipolar disorder – A nationwide Danish register-based study of 19,927 individuals followed for 10 years","authors":"Anders Jorgensen ,&nbsp;Mathilde Marie Brünnich Sloth ,&nbsp;Emma Neble Larsen ,&nbsp;Merete Osler ,&nbsp;Lars Vedel Kessing","doi":"10.1016/j.euroneuro.2025.01.008","DOIUrl":"10.1016/j.euroneuro.2025.01.008","url":null,"abstract":"<div><div>Evidence-based use of pharmacological interventions in bipolar disorder is of paramount clinical importance. We aimed to uncover precription sequences in a large cohort of patients from the first diagnosis of bipolar disorder. Using Danish nationwide registers, we identified individuals with a first-time hospital diagnosis of bipolar disorder between January 1^st, 2001, and December 31^st, 2016. Redemeed prescriptions of litihum, anticonvulsants, antipsychotics, and antidepressants from five years before to five years after diagnosis were retreived. The data were analysed with descriptive statistics, sunburst plots, and Cox proportioal hazard models. The full study population consisted of 19,927 individuals. Before diagnosis, antidepressants were the predominantly prescribed group (46.9 % as first drug). After diagnosis, a major trend towards mood stabilising strategies was observed. although only 18.7 % received lithiumas first prescription. In analyses stratified for illness phase, lithium was more frequently prescribed as first drug after depression than after hypomania/mania, in which antidepressants were used as first drug in 10-15 % of the cases. Treatment sequences were highly heterogeneous (2,459 distinct sequences for the 19,927 individuals under investigation). Lithium appeared to carry the overall highest risk of treatment shift. We conclude that in accordance with national and international guidelines, a diagnosis of bipolar disorder leads to a relevant change of treatment strategy towards mood stabilising drugs. However, lithium continues to be underused;antidepressants probably used too frequently, and treatment sequences are highly heterogeneous and not adjusted according to illness phase. These results point to a potential for optimising the real-world pharmacological management of bipolar disorder.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 51-57"},"PeriodicalIF":6.1,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor concerning: “Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis”","authors":"Chuntong Zhou ,&nbsp;Junjing Miao ,&nbsp;Haiyang Chen ,&nbsp;Liuqing Shi ,&nbsp;Mei Lu ,&nbsp;Mingjie Li ,&nbsp;Huan Han ,&nbsp;Xin Zhou ,&nbsp;Lu Ren","doi":"10.1016/j.euroneuro.2025.01.010","DOIUrl":"10.1016/j.euroneuro.2025.01.010","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Page 16"},"PeriodicalIF":6.1,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylation profile scores of environmental exposures and risk of relapse after a first episode of schizophrenia","authors":"Alex-González Segura ,&nbsp;Llucia Prohens ,&nbsp;Laura Julià ,&nbsp;Silvia Amoretti ,&nbsp;Maria RIbero ,&nbsp;Laura Pino-Camacho ,&nbsp;Guillermo Cano-Escalera ,&nbsp;Anna Mane ,&nbsp;Roberto Rodriguez-Jimenez ,&nbsp;Alexandra Roldan ,&nbsp;Salvador Sarró ,&nbsp;Angela Ibañez ,&nbsp;Judith Usall ,&nbsp;Antonio Lobo ,&nbsp;Clemente Garcia-Rizo ,&nbsp;Manuel Jesus Cuesta ,&nbsp;Mara Parellada ,&nbsp;Ana González-Pinto ,&nbsp;Esther Berrocoso ,&nbsp;Miquel Bernardo ,&nbsp;Concepción De-la-Cámara","doi":"10.1016/j.euroneuro.2025.02.003","DOIUrl":"10.1016/j.euroneuro.2025.02.003","url":null,"abstract":"<div><div>Both genetic and environmental factors have been found to play a significant role in psychosis relapse, either independently or through their synergistic interaction. Recently, DNA methylation (DNAm) has been proposed through the calculation of methylation profile scores (MPS). The aim of the present study is to evaluate the association of MPS as a surrogate marker of the biological impact of early stressful life events (including stressful intrauterine conditions and obstetric complications, childhood adversity and toxic habits), with the risk of schizophrenia (SCZ) relapse. 91 participants from a cohort of first-episode schizophrenia (FES) patients with less than five years of evolution were classified as non-relapse (patients who had not experienced a relapse after 3 years of enrollment) or relapse (patients who relapsed during the 3-year follow-up). As inclusion criteria, patients fulfilled Andreasen's criteria of symptomatic remission. Genome-wide DNA methylation (DNAm) was profiled and fourteen MPS reflecting environmental exposure were constructed including both early stressful life events (including stressful intrauterine conditions and delivery issues, childhood adversity) and toxic habits. Increased levels of MPS reflecting gestational diabetes (<em>p</em> = 0.009), hypertensive disorders during pregnancy (<em>p</em> = 0.004), pre-eclampsia (<em>p</em> = 0.049), early preterm birth (<em>p</em> = 0.030), childhood adversity abuse (<em>p</em> = 0.021) and all childhood adversity (<em>p</em> = 0.030) were significantly associated with an increased risk of relapse. Our study suggests that changes in specific methylation patterns may represent one of the biological mechanisms linking early stressful life events to an increased risk of relapse.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 4-15"},"PeriodicalIF":6.1,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-brain functional neuroimaging correlates of cognitive flexibility impairments in people with mental disorders: A transdiagnostic coordinate-based meta-analysis","authors":"Nicola Meda ,&nbsp;Margherita Baggio ,&nbsp;Enrico Collantoni ,&nbsp;Fabio Sambataro","doi":"10.1016/j.euroneuro.2025.01.009","DOIUrl":"10.1016/j.euroneuro.2025.01.009","url":null,"abstract":"<div><h3>Introduction</h3><div>Set-shifting skills allow individuals to flexibly adapt their behavior against environmental feedback. Impairments of this cognitive control process represent the core features of heterogeneous mental disorders. However, it is unclear whether the neural mechanisms of set-shifting impairments are shared across different mental disorders.</div></div><div><h3>Materials and methods</h3><div>We systematically screened the neuroimaging literature and conducted a coordinate-based meta-analysis. Of 1930 publications, 22 functional neuroimaging studies investigating neural response differences during the performance of set-shifting paradigm on the scanner in individuals with a mental disorder, including schizophrenia, depression, anxiety disorder, neurodevelopmental disorders, eating disorders, obsessive-compulsive disorder, behavioral addiction were selected.</div></div><div><h3>Results</h3><div>We found significant hyperactivation responses during set-shifting in the right medial frontal/anterior cingulate gyrus, the right superior parietal lobule, and the left superior temporal gyrus in patients with schizophrenia, autism spectrum disorders, or generalized anxiety disorder.</div></div><div><h3>Conclusions</h3><div>Our findings suggest a common substrate of increased activity in the frontoparietal network (FPN) across mental disorders during set-shifting. FPN activation responses may represent a biomarker of altered cognition across traditional nosographic categories.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 40-50"},"PeriodicalIF":6.1,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Much ado about nothing?” advocating for neuroscientific research in maternal perfectionism and perinatal mental health disorders","authors":"Chrishanthy Grace Jayarajah","doi":"10.1016/j.euroneuro.2025.02.001","DOIUrl":"10.1016/j.euroneuro.2025.02.001","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Page 19"},"PeriodicalIF":6.1,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study","authors":"Eduard Vieta ,&nbsp;Nahida Ahmed ,&nbsp;Celso Arango ,&nbsp;Anthony J. Cleare ,&nbsp;Koen Demyttenaere ,&nbsp;Markus Dold ,&nbsp;Tetsuro Ito ,&nbsp;Yerkebulan Kambarov ,&nbsp;Stephanie Krüger ,&nbsp;Pierre-Michel Llorca ,&nbsp;Roger S. McIntyre ,&nbsp;Gabriele Sani ,&nbsp;Christian von Holt ,&nbsp;Benoit Rive","doi":"10.1016/j.euroneuro.2024.12.013","DOIUrl":"10.1016/j.euroneuro.2024.12.013","url":null,"abstract":"<div><div>Patients with treatment resistant depression (TRD) experience a greater negative impact on their functioning and productivity at home and in the workplace versus treatment-responsive patients. Here, we report the effects of esketamine nasal spray (NS) versus quetiapine extended release (XR) on functioning, work productivity and activity impairment. ESCAPE‑TRD (NCT04338321) was a 32-week randomised, open‑label, rater‑blinded, active‑controlled phase IIIb study comparing the efficacy and safety of esketamine NS versus quetiapine XR, both alongside an ongoing selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor (SSRI/SNRI), in patients with TRD. Patient functioning was assessed via the Sheehan Disability Scale (SDS; functional remission ≤6). Absenteeism, presenteeism, work productivity loss and activity impairment over time were assessed using the Work Productivity and Activity Impairment: Depression (WPAI:D) questionnaire. Results were cumulated over the entire study duration. Esketamine NS-treated patients (<em>N</em> = 336) experienced 43.2 % more weeks with functional remission versus quetiapine XR-treated patients (<em>N</em> = 340) over the 32-week study period (difference: 2.0 weeks [95 % CI: 0.7, 3.3]; <em>p</em> = 0.0023 [ANCOVA models]). Up to Week 32, esketamine NS-treated patients experienced an 11.9 % reduction in productivity loss due to absenteeism (difference: −1.1 weeks [95 % CI: −2.9, 0.7]; <em>p</em> = 0.2285) and a 14.2 % reduction in overall work productivity loss (difference: –2.3 weeks, 95 % CI: [–3.9, –0.7] <em>p</em> = 0.0045) versus quetiapine XR-treated patients, based on mixed models for repeated measures. Patients receiving esketamine NS experienced greater improvements in functioning and productivity over 32 weeks versus quetiapine XR. These improvements demonstrate the clinical and functional benefit of treatment with esketamine NS for patients with TRD.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 29-39"},"PeriodicalIF":6.1,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia","authors":"Marco Solmi ,&nbsp;Giovanni Croatto ,&nbsp;Nicholas Fabiano ,&nbsp;Stanley Wong ,&nbsp;Arnav Gupta ,&nbsp;Michele Fornaro ,&nbsp;Lynne Kolton Schneider ,&nbsp;S. Christy Rohani-Montez ,&nbsp;Leanne Fairley ,&nbsp;Nathalie Smith ,&nbsp;István Bitter ,&nbsp;Philip Gorwood ,&nbsp;Heidi Taipale ,&nbsp;Jari Tiihonen ,&nbsp;Samuele Cortese ,&nbsp;Elena Dragioti ,&nbsp;Ebba Du Rietz ,&nbsp;Rene Ernst Nielsen ,&nbsp;Joseph Firth ,&nbsp;Paolo Fusar-Poli ,&nbsp;Christoph U. Correll","doi":"10.1016/j.euroneuro.2024.11.001","DOIUrl":"10.1016/j.euroneuro.2024.11.001","url":null,"abstract":"<div><div>The differential influence of sex on premature mortality in schizophrenia is unclear. This study assessed the differences in all-cause and specific cause mortality risks in people with schizophrenia compared to several control groups stratified by sex. We conducted a PRISMA 2020-compliant systematic review and random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) for people with schizophrenia, comparing by sex. We measured publication bias and conducted a quality assessment through the Newcastle-Ottawa scale. We meta-analyzed 43 studies reporting on 2,700,825 people with schizophrenia. Both males and females with schizophrenia had increased all-cause mortality vs. comparison groups (males, RR=2.62, 95%CI 2.35–2.92; females, RR=2.56, 95%CI 2.27–2.87), suicide (males, RR=9.02, 95%CI 5.96–13.67; females, RR=12.09, 95%CI 9.00–16.25), and natural cause mortality (males, RR=2.11, 95%CI 1.88–2.38; females, RR=2.14, 95%CI 1.93–2.38). No statistically significant differences in sex-dependent mortality risk emerged. There was an age-group-dependent increased mortality risk in females &lt; 40 years vs. &gt;/=40 years old (RR=4.23/2.17), and significantly higher risk of death due to neurological disorders (dementia) in males vs. females (RR=5.19/2.40). Increased mortality risks were often associated with specific modifiable risk factors. The increased mortality risk did not improve over time, calling for more studies to identify modifiable factors, and for better physical healthcare for males and females with schizophrenia.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 56-66"},"PeriodicalIF":6.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classical psychedelics in therapy: Essential psychotherapy or minimal support?","authors":"Gitte M Knudsen","doi":"10.1016/j.euroneuro.2025.01.004","DOIUrl":"10.1016/j.euroneuro.2025.01.004","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 27-28"},"PeriodicalIF":6.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}